Filing Details
- Accession Number:
- 0001209191-22-004193
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-20 19:06:02
- Reporting Period:
- 2022-01-18
- Accepted Time:
- 2022-01-20 19:06:02
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1539029 | Clearside Biomedical Inc. | CLSD | Pharmaceutical Preparations (2834) | 452437375 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1815426 | Thomas Ciulla | C/O Clearside Biomedical, Inc. 900 North Point Parkway, Suite 200 Alpharetta GA 30005 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-01-18 | 43,750 | $0.00 | 299,310 | No | 4 | A | Direct | |
Common Stock | Disposition | 2022-01-19 | 9,050 | $2.13 | 295,260 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2022-01-18 | 131,250 | $0.00 | 131,250 | $2.19 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
131,250 | 2032-01-18 | No | 4 | A | Direct |
Footnotes
- These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest in 4 equal annual installments on each of January 18, 2023, January 18, 2024, January 18, 2025 and January 18, 2026, subject to the Reporting Person's continuous service as of each such vesting date.
- The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
- Includes 5,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021.
- One-fourth of the shares underlying this option vest on January 18, 2023 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.